LJP 394: Phase II/III data; Phase III

In a subset of 27 patients with poor renal function in the company's Phase II/III trial, LJPC said that 3 renal flares were observed in 16 patients receiving LJP 394 compared to 6 renal flares in 11 patients on placebo (p=0.097). In 22 patients with both poor renal function and high-affinity antibodies to LJP 394, no flares were observed in 11 patients receiving the therapeutic, compared to 6 flares in the 11 patients receiving placebo (p=0.012). In the Phase II/III trial, 89 percent of patients had high-affinity antibodies to LJP 394, and in those patients time to renal flare was significantly increased in the treatment group compared to the placebo group (p=0.008). ...